Ionis collaborator Flamingo is ready to take flight with 3 antisense drugs in the clinic and mysterious RNA in its sights
As the biggest name in antisense technology, Ionis has long focused on testing the interplay between oligonucleotides and RNA for therapeutic effect. But one class of RNA has mostly stumped researchers — until now.
Flamingo Therapeutics officially debuted Thursday with three clinical and one preclinical cancer drugs handed off from antisense guru Ionis, and an intriguing if unproven discovery engine gunning for mysterious long non-coding RNA targets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.